Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer

BACKGROUND: PARP (poly(ADP‐ribose) polymerase) inhibitors (PARPi) are now standard of care in metastatic castrate‐resistant prostate cancer (mCRPC) patients with select mutations in DNA damage repair (DDR) pathways, but patients with ATM‐ and BRCA2 mutations may respond differently to PARPi. We hypo...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Christopher T., Nizialek, Emily, Berchuck, Jacob E., Vlachostergios, Panagiotis J., Ashkar, Ryan, Sokolova, Alexandra, Barata, Pedro C., Aggarwal, Rahul R., McKay, Rana R., Agarwal, Neeraj, McClure, Heather M., Nafissi, Nellie, Bryce, Alan H., Sartor, Oliver, Sayegh, Nicolas, Cheng, Heather H., Adra, Nabil, Sternberg, Cora N., Taplin, Mary‐Ellen, Cieslik, Marcin, Alva, Ajjai S., Antonarakis, Emmanuel S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099873/
https://www.ncbi.nlm.nih.gov/pubmed/36382533
http://dx.doi.org/10.1002/pros.24454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099873/
https://www.ncbi.nlm.nih.gov/pubmed/36382533
http://dx.doi.org/10.1002/pros.24454

Ejemplares similares